A treatment for atopic dermatitis may help some sinusitis patients regain their sense of smell and taste.
Clinical trials led by Joseph Han, MD, Chief for the EVMS Division of Rhinology and Allergy, found that Dupixent was an effective treatment for adults with severe chronic rhinosinusitis with nasal polyps.
“Many of these patients suffer from severe nasal congestion, drainage, difficulty breathing and a reduced sense of smell and taste,” says Dr. Han, Professor of EVMS Otolaryngology – Head & Neck Surgery. “This treatment significantly improved their quality of life.”
Dupixent is a targeted biologic therapy that inhibits signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key proteins that play a role in inflammation. It was recently approved for use for patients with atopic dermatitis and asthma.
The findings of the phase-3 trials were presented at the Academy of Allergy, Asthma & Immunology 2019 meeting in San Francisco last month.
The U.S. Food and Drug Administration has given priority review designation for Dupixent. Their response is expected by June 26.